Aerobic endurance training during therapy in lymphoma patients
Not Applicable
- Conditions
- C81C62Hodgkin lymphomaMalignant neoplasm of testis
- Registration Number
- DRKS00003894
- Lead Sponsor
- MedizinischeUniversitätsklinik Freiburg Abtl. Häm/Onk
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 72
Inclusion Criteria
patients with the fist diagnosis of a malignant lymphoma or a relapse of it
indication for chemotherapy, immunotherapy or radiotherapy
age >= 18
Karnofsky > 60
no pregnancy
informed consense
proximity
Exclusion Criteria
absolute: risk of thrombosis
uncontrolled hypertension with drugs > 180 sys mmHG or > 100 dias mmHG
angina pectoris
myocardial infarction
NYHA III - IV
bone metastasis with risk of fracture
relative:
infection with fever >= 38.0°
i.v. antibiotics
platelets < 30.000
leukocytes < 1000
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method improvement of QoL Fatigue<br>improvement of QoL (EORTC QLQ-C30)
- Secondary Outcome Measures
Name Time Method 1. improvement of endurance and strength: Improvement of PWC 130 an 1 RM measure<br>2. improvement of movement coordination and -type measured in the FBKS and BKT-Tur<br>3. improvement of self assessment measured with FPI R 4<br>4. improvement of time to progression and OS: TTP and OS measurement<br>5. reduction of therapy associated side effects: Measurement of the NCI CTC criteria<br>6 preservation or improvement of nutrition assessment: measurement: lean body mas, reduction fat mass, BMI,BIA, SGA